1
Combined with risk scoring, SMB appears to identify patients at lower risk.
2
Evidence for risk factors to identify patients with kidney disease is limited.
3
Biomarkers might be able to identify patients at highest risk of progression.
4
This gene signature may identify patients that could benefit from IFN-based therapies.
5
Conclusions: Several patient and clinical factors identify patients at higher risk of readmission.
6
Conclusion: We developed a clinical score to identify patients with possible autoinflammatory IFNopathies.
7
Serial platelet monitoring may help identify patients at higher risk of postoperative complications.
8
Risk factors are used to identify patients with pre-existent kidney disease.
9
The rule may identify patients at high risk of invasive candidiasis.
10
Aim: To explore patient preferences and to identify patients' beliefs about LBP treatments.
11
We sought to identify patients at high risk of missing visits.
12
Immune-monitoring protocols are needed to identify patients who may benefit from immunomodulatory trials.
13
The miR-210 levels identify patients with acute rejection and predict long-term kidney function.
14
It can be used to identify patients with diastolic dysfunction and predict PCWP.
15
We investigated the ability of emergency physicians to accurately identify patients with stroke.
16
These variables were used to identify patients with good, intermediate, and poor prognoses.
